top of page

Atf4 Protects Islet β-Cell Identity and Function Under Acute Glucose-Induced Stress but Promotes β-Cell Failure in the Presence of Free Fatty Acid

  • bgtaylor1
  • Jul 29
  • 2 min read

Logo for the National Institutes of Health

Date:

May 1, 2025

PMID:

39899446

Category:

N/A

Authors:

Mahircan Yagan, Sadia Najam, Ruiying Hu, Yu Wang, Mathew T Dickerson, Prasanna K Dadi, Yanwen Xu, Alan J Simmons, Roland Stein, Christopher M Adams, David A Jacobson, Ken S Lau, Qi Liu, Guoqiang Gu

Abstract:


Glucolipotoxicity, caused by combined hyperglycemia and hyperlipidemia, results in β-cell failure and type 2 diabetes via cellular stress-related mechanisms. Activating transcription factor 4 (Atf4) is an essential effector of stress response. We show here that Atf4 expression in β-cells is minimally required for glucose homeostasis in juvenile and adolescent mice but it is needed for β-cell function during aging and under obesity-related metabolic stress. Henceforth, Atf4-deficient β-cells older than 2 months after birth display compromised secretory function under acute hyperglycemia. In contrast, they are resistant to acute free fatty acid-induced dysfunction and reduced production of several factors essential for β-cell identity. Atf4-deficient β-cells downregulate genes involved in protein translation. They also upregulate several lipid metabolism or signaling genes, likely contributing to their resistance to free fatty acid-induced dysfunction. These results suggest that Atf4 activation is required for β-cell identity and function under high glucose. But Atf4 activation paradoxically induces β-cell failure in high levels of free fatty acids. Different transcriptional targets of Atf4 could be manipulated to protect β-cells from metabolic stress-induced failure.


Acknowledgements:

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, or the National Institute of Health.


The Translational and Basic Science Research in Early Lesions (TBEL) Research Consortia is supported and funded by grants from the National Cancer Institute and the National Institutes of Health under the following award numbers:


Project Number:

Awardee Organization

U54CA274374

Fred Hutchinson Cancer Center

U54CA274375

Houston Methodist Research Institute

U54CA274370

Johns Hopkins University

U54CA274371

UT MD Anderson Cancer Center

U54CA274367

Vanderbilt University Medical Center


留言

評等為 0(最高為 5 顆星)。
暫無評等

新增評等
bottom of page